SCHEMBL797991

SCHEMBL797991

C=CCc1cc(CC=C)nc(CC=C)c1

nearest known ligand 0.41

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
XDH P47989 1/20 0.40
ALDH1A1 P00352 6/20 0.39
MAPT P10636 5/20 0.39
GAA P10253 4/20 0.39
MEN1 O00255 3/20 0.39
KMT2A Q03164 3/20 0.39
PPARG P37231 2/20 0.39
PPARD Q03181 2/20 0.39
KDM4E B2RXH2 2/20 0.39
GABRA1 P14867 2/20 0.39
CNR1 P21554 2/20 0.39
CNR2 P34972 2/20 0.39
GABRB2 P47870 2/20 0.39
ALDH2 P05091 1/20 0.39
AKR1B1 P15121 1/20 0.39
HPGD P15428 1/20 0.39
NPSR1 Q6W5P4 1/20 0.39
PPARA Q07869 1/20 0.36
TNKS O95271 2/20 0.36
PARP1 P09874 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL9301795 0.82 GABRA1 (0.35) XDHALDH1A1MAPTGAAMEN1
SCHEMBL9346680 0.78 IMPDH2 (0.33) XDHNPSR1
SCHEMBL215399 0.78 XDH (0.50) XDHALDH1A1MAPTGAAMEN1
SCHEMBL14877309 0.76 PTGS2 (0.44) MEN1KMT2ACNR1CNR2CYP3A4
SCHEMBL2556929 0.75 XDH (0.45) XDHALDH1A1MAPTGAAMEN1
SCHEMBL10339189 0.73 XDH (0.39) XDHALDH1A1MAPTGAAMEN1
SCHEMBL22469881 0.73 XDH (0.39) XDHALDH1A1MAPTGAAMEN1
SCHEMBL10582024 0.73 IMPDH2 (0.33) XDHNPSR1
SCHEMBL9403340 0.73 PDE4A (0.36) GABRA1GABRB2PDE4APDE4CPDE4D
SCHEMBL11458793 0.73 DCTPP1 (0.31) GABRA1GABRB2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 81 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20080200648-A1 Avoids undesired epimerisation of alpha-carbon of C-terminal amino acid; acidolysis LONZA AG (CH) 2008-08-21 US claimed
EP-1771463-B1 METHOD OF PEPTIDE SYNTHESIS LONZA AG (CH) 2008-01-02 EP claimed
EP-1771463-A1 METHOD OF PEPTIDE SYNTHESIS LONZA AG (CH) 2007-04-11 EP claimed
WO-2006008050-A1 METHOD OF PEPTIDE SYNTHESIS LONZA AG (CH) 2006-01-26 WO claimed
EP-0104984-B1 VINYLCARBAMIC ACID ESTERS AND THEIR PREPARATION SOCIETE NATIONALE DES POUDRES ET EXPLOSIFS (FR) 1990-05-16 EP claimed
EP-0104984-A2 Vinylcarbamic acid esters and their preparation SOCIETE NATIONALE DES POUDRES ET EXPLOSIFS (FR) 1984-04-04 EP claimed
CN-120152714-A Anti-inflammatory compounds, pharmaceutical compositions, and methods of treating hemochromatosis and other diseases 米拉洛克斯有限责任公司 2025-06-13 CN disclosed
EP-3414257-B1 METHOD FOR PREPARATION OF LIRAGLUTIDE USING BAL LINKER POLYPEPTIDE LABORATORIES HOLDING PPL AB (SE) 2023-06-07 EP disclosed
EP-3405476-B1 METHOD FOR PREPARATION OF PEPTIDES WITH psWANG LINKER POLYPEPTIDE LABORATORIES HOLDING PPL AB (SE) 2022-05-18 EP disclosed
US-11236123-B2 Method for preparation of peptides with psWang linker POLYPEPTIDE LABORATORIES HOLDING (PPL) AB (SE) 2022-02-01 US disclosed
US-11174298-B2 Preparation and use of ginsentides and ginsentide-like peptides Tam, James P. (SG) 2021-11-16 US disclosed
US-20210155665-A1 METHOD FOR PREPARING INTERLEUKIN-2 OR INTERLEUKIN-2 ANALOGUES ETH ZURICH (CH) 2021-05-27 US disclosed
US-20200277343-A1 PREPARATION AND USE OF GINSENTIDES AND GINSENTIDE-LIKE PEPTIDES NANYANG TECHNOLOGICAL UNIVERSITY (SG) 2020-09-03 US disclosed
WO-2006048144-A1 CYCLIZATION OF A PEPTIDE LONZA AG (CH) 2006-05-11 WO disclosed
WO-2006045603-A1 S-ALKYL-SULPHENYL PROTECTION GROUPS IN SOLID-PHASE SYNTHESIS LONZA AG (CH) 2006-05-04 WO disclosed
WO-2006045483-A2 ON-RESIN PEPTIDE CYCLIZATION LONZA AG (CH) 2006-05-04 WO disclosed
WO-2006032457-A1 PEPTIDE CYCLISATION LONZA AG (CH) 2006-03-30 WO disclosed
WO-2006008050-A1 METHOD OF PEPTIDE SYNTHESIS LONZA AG (CH) 2006-01-26 WO disclosed
US-5026933-A Mixture of mono-olefins, alkylation, sulfonation MOBIL OIL CORPORATION (US) 1991-06-25 US disclosed
US-4870038-A NEUTRALIZED WITH 2,4,6-COLLIDINE; LINEAR OLIGOMERS MOBIL OIL CORPORATION (US) 1989-09-26 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-11174298-B2 Preparation and use of ginsentides and ginsentide-like peptides NPR1, RXFP1, NPR3 XDH 3620/4885ALDH1A1 2760/4885MAPT 4866/4885
US-20080200648-A1 Avoids undesired epimerisation of alpha-carbon of C-terminal amino acid; acidolysis NGLY1, PTMS, ANPEP XDH 4360/4885ALDH1A1 4354/4885MAPT 4139/4885
US-20200277343-A1 PREPARATION AND USE OF GINSENTIDES AND GINSENTIDE-LIKE PEPTIDES NPR1, RXFP1, NPR3 XDH 3620/4885ALDH1A1 2760/4885MAPT 4866/4885
US-11236123-B2 Method for preparation of peptides with psWang linker VIP, GLP1R, IAPP XDH 4768/4885ALDH1A1 4859/4885MAPT 3425/4885
US-20210155665-A1 METHOD FOR PREPARING INTERLEUKIN-2 OR INTERLEUKIN-2 ANALOGUES IL2, IL2RA, IL1A XDH 4706/4885ALDH1A1 2061/4885MAPT 3027/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.